The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases

European Journal of Human Genetics

Volumn 18, Issue 7, 2010, Pages 856-858

  Zanna, Ines ^a   Rizzolo, Piera ^b   Sera, Francesco ^a   Falchetti, Mario ^b   Aretini, Paolo ^a   Giannini, Giuseppe ^b   Masala, Giovanna ^a   Gulino, Alberto ^b   Palli, Domenico ^a   Ottini, Laura ^b  

^a CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BRCAPRO 5.0 prediction model; Male breast cancer; Risk assessment

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL EFFECTIVENESS; COMPUTER PROGRAM; DISCRIMINANT ANALYSIS; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

AREA UNDER CURVE; BREAST NEOPLASMS, MALE; FEMALE; GENETIC COUNSELING; HUMANS; MALE; MODELS, GENETIC; ROC CURVE; SOFTWARE;

NUCLEOPOLYHEDROVIRUS;

EID: 77953762408     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2010.29     Document Type: Article

References (23)

1. Frank TS, Deffenbaugh AM, Reid JE et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10 000 individuals. J Clin Oncol 2002; 20: 1480-1490.
2. Gilpin CA, Carson N, Hunter AG: A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet 2000; 58: 299-308.
3. Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998; 62: 145-158.
4. Berry DA, Iversen Jr ES, Gudbjartsson DF et al: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002; 20: 2701-2712.
5. Marroni F, Aretini P, D'Andrea E et al: Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet 2004; 12: 899-906.
6. Capalbo C, Ricevuto E, Vestri A et al: Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software. Eur J Hum Genet 2006; 14: 49-54.
7. Barcenas CH, Hosain GM, Arun B et al: Assessing BRCA carrier probabilities in extended families. J Clin Oncol 2006; 24: 354-360.
8. Antoniou AC, Durocher F, Smith P, Simard J, Easton DF: BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 2006; 8: R3.
9. Panchal SM, Ennis M, Canon S, Bordeleau LJ: Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Med Genet 2008; 9: 116.
10. Kurian AW, Gong GD, Chun NM et al: Performance of BRCA1/2 mutation prediction models in Asian Americans. J Clin Oncol 2008; 26: 4752-4758.
11. Kurian AW, Gong GD, John EM et al: Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2009; 18: 1084-1091.
12. Chen S, Blackford AL, Parmigiani G: Tailoring BRCAPRO to Asian-Americans. J Clin Oncol 2009; 27: 642-643; author reply 643-644.
13. Pasanisi P, Hedelin G, Berrino J et al: Oral contraceptive use and BRCA penetrance: a case-only study. Cancer Epidemiol Biomarkers Prev 2009; 18: 2107-2113.
14. Brinton LA, Richesson DA, Gierach GL et al: Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 2008; 100: 1477-1481.
15. Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A: Male breast cancer. Crit Rev Oncol Hematol 2010; 73: 141-155.
16. Ottini L, Rizzolo P, Zanna I et al: BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat 2009; 116: 577-586.
17. Falchetti M, Lupi R, Rizzolo P et al: BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 2008; 110: 161-167.
18. Papi L, Putignano AL, Congregati C et al: Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. Breast Cancer Res Treat 2009; 117: 497-504.
19. Chen S, Wang W, Broman KW et al: BayesMendel: an R Environment for Mendelian risk prediction. Stat Appl Genet Mol Biol 2004; 3: 1-16.
20. Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-1333.
21. Tai YC, Domchek S, Parmigiani G, Chen S: Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99: 1811-1814.
22. Parmigiani G, Chen S, Iversen Jr ES et al: Validity of models for predicting BRCA 1 and BRCA2 mutations. Ann Intern Med 2007; 147: 441-450.
23. Kang HH, Williams R, Leary J, Ringland C, Kirk J, Ward R: Evaluation of models to predict BRCA germline mutations. Br J Cancer 2006; 95: 914-920.